PMID- 32017292
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 29
IP  - 2
DP  - 2020 Feb
TI  - Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with 
      type 2 diabetes mellitus: A systematic review and meta-analysis.
PG  - 161-172
LID - 10.1002/pds.4943 [doi]
AB  - PURPOSE: This study aimed to systematically evaluate the association between 
      sodium-glucose cotransporter 2 (SGLT2) inhibitors and pancreatic safety in 
      patients with type 2 diabetes mellitus (T2DM). METHODS: Electronic databases were 
      searched before September 2019 to include randomized controlled trials (RCTs) of 
      SGLT2 inhibitors that reported any event on pancreatitis or pancreatic cancer 
      among patients with T2DM. Peto odds ratio (OR) with 95% confidence interval (CI) 
      was used to pool the data. The GRADE framework was introduced to assess the 
      quality of evidence. RESULTS: Of the 35 trials involving 44 912 patients with 
      T2DM included, 41 events of acute pancreatitis (19 trials; 32 932 patients), 72 
      events of overall pancreatitis (including acute pancreatitis, chronic 
      pancreatitis, or nonspecific pancreatitis; 26 trials; 36 688 patients), and 40 
      events of pancreatic cancer (18 trials; 27 806 patients) were reported during a 
      median follow-up of 52 weeks. SGLT2 inhibitors were not associated with an 
      increased risk of acute pancreatitis compared to controls (placebo or other 
      active drugs; Peto OR, 1.13; 95% CI, 0.60-2.13; moderate quality evidence). A 
      similar result was found for risk of overall pancreatitis (Peto OR, 1.08; 95% CI, 
      0.67-1.75; moderate quality evidence) and pancreatic cancer (Peto OR, 1.34; 95% 
      CI, 0.71-2.54; very low-quality evidence). CONCLUSIONS: Moderate quality evidence 
      from RCTs shows no significantly increased risk of acute pancreatitis associated 
      with SGLT2 inhibitors, while there is very low-quality evidence suggesting no 
      significant association between SGLT2 inhibitors and pancreatic cancer among 
      patients with T2DM.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Tang, Huilin
AU  - Tang H
AUID- ORCID: 0000-0002-5814-6657
AD  - Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana 
      University, Indiana.
FAU - Yang, Keming
AU  - Yang K
AD  - Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana 
      University, Indiana.
FAU - Li, Xin
AU  - Li X
AD  - Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana 
      University, Indiana.
FAU - Song, Yiqing
AU  - Song Y
AUID- ORCID: 0000-0002-2097-7332
AD  - Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana 
      University, Indiana.
FAU - Han, Jiali
AU  - Han J
AUID- ORCID: 0000-0002-8309-7092
AD  - Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana 
      University, Indiana.
AD  - Melvin and Bren Simon Cancer Center, Indiana University, Indiana.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy/*epidemiology
MH  - Humans
MH  - Pancreas/*drug effects/pathology
MH  - Pancreatic Neoplasms/chemically induced/*epidemiology
MH  - Pancreatitis/chemically induced/*epidemiology
MH  - Randomized Controlled Trials as Topic/methods
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - SGLT2 inhibitors
OT  - acute pancreatitis
OT  - meta-analysis
OT  - pancreatic cancer
OT  - pharmacoepidemiology
OT  - type 2 diabetes
EDAT- 2020/02/06 06:00
MHDA- 2021/01/23 06:00
CRDT- 2020/02/05 06:00
PHST- 2019/06/19 00:00 [received]
PHST- 2019/11/07 00:00 [revised]
PHST- 2019/11/25 00:00 [accepted]
PHST- 2020/02/05 06:00 [entrez]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
AID - 10.1002/pds.4943 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2020 Feb;29(2):161-172. doi: 10.1002/pds.4943.